About
4.04USD+0.00 +0.00%
Closed • Updated at 03:43 GMT+00:00Market Cap$381.05M
Volume177.8K
Beta1.22
RSI48.87
Gross Margin79.04%
X4 Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 6 2026
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Apr 29 2026
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
Mar 17 2026
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 4 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Mar 2 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Community Chat
Ask AI
Try asking
Translate